asthma chronic obstructive pulmonary disease copd characterized chronic airway inflammation patients copd certain patients asthma little therapeutic benefit existing corticosteroid therapies urgent need novel strategies transcription factor nuclear nfkappab central inflammation necessary expression numerous inflammatory genes proinflammatory cytokines including interleukin tumor necrosis factor activate ikappab kinase complex ikk promote degradation inhibitory ikappab proteins activate pathway particular main ikappab kinase ikk2 considered prime targets novel drugs used adenoviral overexpression demonstrate ikk2 dependence key inflammatory genes including intercellular adhesion molecule cyclooxygenase2 granulocyte factor regulated activation normal t cell expressed secreted rantes monocyte chemotactic mcp1 oncogenealpha groalpha protein2 epithelial neutrophil activating peptide NUMBER primary human airways smooth muscle cells cell type central pathogenesis airway inflammatory diseases data predict beneficial effect ikk2 inhibition validated outputs used evaluate novel ikk inhibitors nicotinamide ml120b expression compared corticosteroid dexamethasone observed il6 il8 gmcsf rantes groalpha expression reduced ikk inhibitors furthermore inhibition effective mcp1 groalpha effective maximally effective concentration dexamethasone suggest ikk inhibitors considerable benefit inflammatory airways diseases particularly copd severe asthma corticosteroids ineffective anti inflammatory factor kappab il 1beta tnf alpha nf kappab anti inflammatory nf kappab icam NUMBER il NUMBER macrophage colony stimulating gm csf protein NUMBER growth regulated neutrophil activating nap NUMBER ena NUMBER n NUMBER chloro 9h beta carbolin NUMBER yl ps NUMBER n NUMBER chloro NUMBER methoxy 9h beta carbolin NUMBER yl NUMBER methyl nicotinamide il 1beta tnfalpha induced icam NUMBER il NUMBER mcp NUMBER nap NUMBER ena NUMBER icam NUMBER nap NUMBER